13 completed. 13 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 13 |
| Phase 1 | 1 | Completed 1 |
Follow Insulinoma: new trials by email Literature Review of Insulinoma trials Research Report on Insulinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors regorafenib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | University of Southern California | 3 | 2016-08-16 | 2021-12-15 |
| 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH 68Ga-NODAGA-exendin 4 PET/CT - Insulinoma | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 56 | 2015-04-01 | 2021-06-16 |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors temozolomide, capecitabine - Gastrinoma, Glucagonoma | Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 144 | 2013-08-08 | 2026-09-29 |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Capecitabine, Temozolomide, Bevacizumab - Gastrinoma, Glucagonoma | Phase 2 | Completed | Shaheen Shagufta | 20 | 2012-12-01 | 2024-02-06 |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors AMG 706, octreotide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Eastern Cooperative Oncology Group | 46 | 2008-11-07 | 2023-07-05 |
| Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2007-03-01 | 2020-04-03 |
| Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors capecitabine, cisplatin, streptozocin - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 84 | 2005-08-01 | 2013-08-07 |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors sorafenib tosylate - Gastrinoma, Glucagonoma | Phase 2 | Completed | National Cancer Institute (NCI) | 93 | 2005-06-01 | 2014-11-17 |
| Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer isolated perfusion, melphalan - Cancer | Phase 2 | Completed | Delcath Systems Inc. | 56 | 2004-09-01 | 2013-10-23 |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery fluorouracil, irinotecan hydrochloride, leucovorin calcium - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Federation Francophone de Cancerologie Digestive | 20 | 2004-05-01 | 2016-05-30 |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors gefitinib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | National Cancer Institute (NCI) | 90 | 2003-12-01 | 2013-06-04 |
| PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors bortezomib - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 2001-04-01 | 2013-01-31 | |
| Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors thalidomide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 2001-03-01 | 2013-06-18 |
Glucagonoma (12) · Somatostatinoma (12) · Carcinoma, Islet Cell (10) · Gastrinoma (10) · Adenoma, Islet Cell (6) · Vipoma (6) · Neoplasms (4) · Neuroendocrine Tumors (2) · Pancreatic Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Appendiceal Neoplasms (1) · Bile Duct Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Medullary (1)
Adenoma (13) · Digestive System Diseases (13) · Digestive System Neoplasms (13) · Endocrine Gland Neoplasms (13) · Endocrine System Diseases (13) · Neoplasms by Histologic Type (13) · Neoplasms by Site (13) · Neoplasms, Glandular and Epithelial (13) · Pancreatic Diseases (13) · Adenocarcinoma (12) · Carcinoma (12) · Carcinoma, Neuroendocrine (12) · Neoplasms, Germ Cell and Embryonal (12) · Neuroectodermal Tumors (12) · Pancreatic Neoplasms (11)
Capecitabine (3) · Temozolomide (2) · Bevacizumab (1) · Bortezomib (1) · Cisplatin (1) · Fluorouracil (1) · Gefitinib (1) · Irinotecan (1) · Leucovorin (1) · Melphalan (1) · Octreotide (1) · Sorafenib (1) · Streptozocin (1) · Thalidomide (1) · batifiban (1)
National Cancer Institute (NCI) (3) · Cambridge University Hospitals NHS Foundation Trust (1) · Delcath Systems Inc. (1) · ECOG-ACRIN Cancer Research Group (1) · Eastern Cooperative Oncology Group (1) · Federation Francophone de Cancerologie Digestive (1) · Memorial Sloan Kettering Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1) · Radboud University Medical Center (1) · Shaheen Shagufta (1) · University of Southern California (1)
United States (10) · United Kingdom (1)
Timothy Hobday (2) · Guillaume Cadiot (1) · James Yao (1) · Leonard B. Saltz, MD (1) · Manisha H. Shah, MD (1) · Martin Gotthardt, Prof. Dr. (1) · Mary Mulcahy, MD (1) · Marybeth Hughes, MD (1) · Pamela Kunz (1) · Pippa Corrie, PhD, FRCP (1) · Shaheen Shagufta, MD (1) · Syma Iqbal, MD (1) · Tim Meyer, MD, BSc, MRCP, PhD (1)
PMID 21831734, PMID 25956795, PMID 29853660, PMID 36260828
N01CM62205 (2), 2014 (1), N01CM62202 (1), P30CA014089 (1), P30CA016672 (1), U01CA062490 (1), U10CA021115 (1), U10CA023318 (1), U10CA180820 (1)